Healthcare Stocks: What Analysts Are Saying About Pfizer and Oneview

Investors are keeping a close eye on healthcare stocks, especially Pfizer and Oneview Healthcare. Both companies have been under the microscope lately, with analysts sharing their thoughts on where these stocks might be headed. Pfizer, a big name in the pharmaceutical world, has seen some mixed reviews. Justin Smith from Bernstein recently kept his "Hold" rating on the stock, setting a price target of $30. 00. This is a bit higher than where Pfizer's shares closed last week at $24. 79, which is near its lowest point in the past year. Not everyone agrees with Smith, though. Another analyst recently downgraded Pfizer to a "Hold" with a slightly lower price target of $26. 00. Overall, the general feeling among analysts is a "Moderate Buy, " with an average price target of $28. 40. That's a potential 13. 7% increase from where the stock is now. Oneview Healthcare, on the other hand, is a smaller player in the healthcare tech space. Martyn Jacobs from Bell Potter has given it a "Buy" rating, with a price target of A$0. 34. Oneview's shares closed last week at $0. 16, which is also its highest point in the past year. Jacobs isn't the only one bullish on Oneview. The overall consensus among analysts is a "Moderate Buy, " with an average price target of $0. 23. However, it's important to note that Jacobs is ranked quite low among analysts, which might make investors think twice before jumping in. When looking at these stocks, it's crucial to consider more than just analyst ratings. Factors like market trends, company performance, and broader economic conditions can all play a big role in how these stocks perform in the future. Investors should do their own research and think critically about where they put their money.